Review Article
Detection of Circulating Tumor Cells

Sanne de Wit, Guus van Dalum, and Leon W. M. M. Terstappen

Department of Medical Cell BioPhysics, Faculty of Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Carre, Room C4437, Hallenweg 23, 7522 NH Enschede, The Netherlands

Correspondence should be addressed to Leon W. M. M. Terstappen; l.w.m.m.terstappen@utwente.nl

Received 2 March 2014; Accepted 17 May 2014; Published 15 July 2014

Academic Editor: Hiroki Yoshida

Copyright © 2014 Sanne de Wit et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The increasing number of treatment options for patients with metastatic carcinomas has created an accompanying need for methods to determine if the tumor will be responsive to the intended therapy and to monitor its effectiveness. Ideally, these methods would be noninvasive and provide quantitative real-time analysis of tumor activity in a variety of carcinomas. Assessment of circulating tumor cells shed into the blood during metastasis may satisfy this need. Here we review the CellSearch technology used for the detection of circulating tumor cells and discuss potential future directions for improvements.

1. Introduction

In 1869, Thomas Ashworth described the microscopic observation of circulating tumor cells (CTC) in the blood of a man with metastatic cancer. He concluded that the CTC must have passed through the circulatory system to arrive at the vein from which the blood was collected [1]. The critical role that circulating tumor cells play in the metastatic spread of carcinomas has been demonstrated more than 100 years later [2]. Only recently technology has become available with the requisite sensitivity and reproducibility to explore the diagnostic potential of CTC [3].

Via a rigorous clinical testing program, CellSearch is the only system validated for CTC detection to date [4–10]. The device is cleared by the FDA for the monitoring of patients with metastatic breast, colorectal, and prostate cancer and clinical utility has also been demonstrated in metastatic small and non-small cell lung cancer [11, 12], stomach cancer [13], pancreas cancer [14], ovarian cancer [15], and bladder cancer [16–18].

For the enumeration of CTC, the CellSearch reagent kit uses ferrofluids labeled with the epithelial cell adhesion molecule (EpCAM), a DNA dye to stain nuclei and antibodies to target CD45 and cytokeratin 8, 18, and 19. The enrichment of endothelial and melanoma cells was enabled by replacing EpCAM ferrofluids with CD146 ferrofluids in the CellSearch system. Replacement of cytokeratin antibodies with CD105 allowed the enumeration of endothelial cells and studies showed an increase in endothelial cells in metastatic cancer and cardiovascular diseases [19–21]. Replacement of cytokeratin antibodies with antibodies to high molecular weight melanoma antigen allowed the enumeration of melanoma cells and their presence is associated with a poor prognosis [22].

The potential to assess the presence of treatment targets in CTC such as Bcl-2 [23], Her-2 [24, 25], AR [26], and IGFR1 [27] at both the DNA and protein level by the CellSearch system has spurred the interest in this field as it holds the promise of a “real time liquid biopsy.”

2. Cancer and the Formation of Metastasis

In the USA, 1.7 million people are expected to be diagnosed with cancer and 0.6 million people are expected to die from cancer [28]. At present, cancer is the second leading cause of mortality in USA and Europe [28, 29]. Although the 5-year relative survival rate for all cancers is improving (49% in 1975–1977 and 68% in 2002–2008), the number of people diagnosed with cancer is expected to increase due to the increase in age of the overall population. The improvement in survival reflects both progress in diagnosing certain cancers...
at an earlier stage and improvements in treatment. The costs associated with these improvements are however also increasing and will have an enormous economic impact in the time to come.

Death of cancer patients is rarely caused by the primary tumor and can be contributed in most cases to metastases at distant sites. Understanding the metastatic process is therefore of utmost importance to get more insight into the prognosis of patients and to identify potential ways to prevent tumors to form metastases. Figure 1 illustrates the evolution of cancer. At the early stages of tumor cell formation, diversity of the tumor cells already occurs and some will gain a greater ability than other cells to expand (tumor stem cells). At the time a tumor reaches ~100 μm in diameter, its need for nutrients increases. This is supplied through neovascularization, which permits the tumor to grow. At this time, cells from the tumor can enter the blood either directly or through the lymphatic system. Although the majority of these cells will succumb, some will survive and either passively or actively penetrate the endothelial cell layer at different sites in the body, forming distant metastasis that ultimately will kill the patient.

Cancers have preferences for certain tissues to form metastasis. The mechanisms and antigens expressed on their cell surface and the ligands on the capillaries of that specific tissue are still poorly understood. As time passes, the diversity of tumor cells increases, making the treatment more difficult. Moreover, the diversity further increases under the influence of therapy as tumor cells become resistant to therapy. Today, the potential sensitivity of a tumor is assessed on tumor cells taken at the time of surgery. In cases that the tumor has not been completely irradiated from the body tumor cells, tumor cells will remain dormant or will expand. At the time the tumor cells have formed a detectable metastasis, the cells may no longer have the same sensitivity to therapies as at the time of surgery. This makes it again necessary to obtain a tumor biopsy and assess the best treatment options. However, biopsies are difficult, if not impossible, to take from metastatic sites. The ability to isolate tumor cells from the blood provides a unique opportunity for a "real time liquid biopsy." Of course, detection of cancer before dissemination has taken place is preferred. However, to make this possible, a leap in technology development is required. It has been modeled that tumors are very small at the moment of dissemination, and traditional imaging techniques need to be improved to detect these small tumors [30]. Also, to detect CTC in such early disease conditions, sensitivity of these tests will need to be improved significantly [30].

3. Identification of CTC by the CellSearch System

The CellSearch system (Janssen Diagnostics, LLC; Raritan, NJ) consists of the CellTracks Autoprep, CellTracks Magnest, CellSearch Epithelial Cell Kit, and the CellTracks Analyzer II. The reagent kit used for the enumeration of CTC (CellSearch Epithelial Cell Kit) contains ferrofluids labeled with EpCAM to select for cells of epithelial origin, the staining reagents 4',2-diamidino-2-phenylindole, dihydrochloride (DAPI) for a nuclear stain, CD45-allophycocyan (CD45-APC) to label leukocytes, cytokeratin 8, 18 Phycoerythrin, and cytokeratin 19 Phycocerythrin (CK-PE) to label cells of epithelial origin, and buffers to enhance cell capture and permeabilize and fix the cells [31, 32]. Samples that will be processed up to 96 hours after collection are drawn into 10 mL evacuated blood draw tubes (Janssen Diagnostics, LLC; Raritan, NJ) and maintained at room temperature.

To obtain viable CTC or investigate the expression of RNA in CTC, blood should be collected in EDTA and preferably processed within 24 hours. For these experiments the CellSearch Profile Kit (Janssen Diagnostics, LLC; Raritan, NJ) should be used. In this kit epithelial derived cells are enriched by the use of ferrofluids labeled with antibodies targeting the EpCAM antigen. After processing with the CellTracks Autoprep, a cell suspension is obtained including the CTC and ~5000 residual leukocytes. This number will increase with the age of the blood samples. These samples can be used to investigate the mRNA expression of CTC or analyzed at the single cell level after staining and sorting by, for example, flow cytometry [33, 34].

The CellTracks Autoprep immunomagnetically enriches cells expressing EpCAM from 7.5 mL of blood and fluorescently labels the enriched cells with DAPI, CD45-APC, and CK-PE. The resuspended cells are deposited in the cartridge that is positioned in the CellTracks Magnest. This semi-automated fluorescence-based microscopy system acquires images using a 10X NA0.45 objective with filters for DAPI, PE, APC, and FITC (not used) to cover the complete surface area of the analysis chamber. A computer identifies objects staining with DAPI and PE in the same location and generates images for the DAPI, PE, APC, and FITC filters. Figure 2
The number of cells with features that are consistent with those of CTC detected with the CellSearch system in 7.5 mL of blood from healthy donors or patients with nonmalignant diseases is remarkably low [3]. Lowering the stringency of the criteria to assign cells or objects increases the number of CTC detected in both controls and patients [36, 39]. The limited number of controls tested and less strict criteria to assign objects as CTC are an important reason for the high number of CTC reported by new technologies for detection of CTC. In fact, our earlier work used flow cytometry as the platform to analyze the immunomagnetically enriched samples and the number of CTC detected in both controls and patients was clearly higher. This can be contributed to the less stringent criteria, such as a no-cell morphology criterion [41, 42].

Many new studies have reported the frequency of CTC detected by the CellSearch system, since the original report on the frequency of CTC detected with the CellSearch system in controls and patients with a variety of carcinomas [3]. Table 1 provides a summary of the frequency of CTC at various thresholds reported in these studies in several carcinomas, healthy donors, and patients with nonmalignant diseases. If CTC are to be used for the assessment of treatment targets to choose the most appropriate therapy, sufficient number of CTC will need to be available for detailed analysis. The heterogeneity of the tumor cells forces one to examine multiple individual cells and a minimum of 10–100 cells seems reasonable [25, 26, 43–45]. Table 1, however, shows that the number of patients (n) with sufficient number of CTC in 7.5 mL of blood for this purpose is very low. Therefore, the number of CTC in larger volumes of blood was estimated by fitting the frequency distribution of CTC present in 7.5 mL of blood [46]. Figure 3 shows the frequency distribution of CTC detected in 7.5 mL of blood by the CellSearch system in patients with metastatic breast cancer (stair plot green line), metastatic colorectal cancer (stair plot blue line), and metastatic prostate cancer (stair plot red line). The solid lines show the best fit for this distribution and the dotted line is the 95% confidence level around this distribution. This figure shows that a 100-fold increase in blood volume is needed to detect CTC in all patients. All the blood will need to be analyzed to obtain sufficient number of CTC for characterization and guidance of therapy.

### 4. Frequency of CTC Detected by the CellSearch System

The presence of CTC is associated with a relative poor prognosis. This was demonstrated in prospective multicenter studies in metastatic colorectal cancer [8], prostate cancer [10], and breast cancer [4]. A discrimination between patients with favorable CTC (<3 for colorectal cancer or <5 for breast and prostate cancer) and unfavorable CTC (≥3 or ≥5) was made in the original papers reporting the results of these studies. In practice, a further discrimination in patients with unfavorable CTC can be made when the actual peripheral

### 5. Relation between Presence of CTC and Survival

The presence of CTC is associated with a relative poor prognosis. This was demonstrated in prospective multicenter studies in metastatic colorectal cancer [8], prostate cancer [10], and breast cancer [4]. A discrimination between patients with favorable CTC (<3 for colorectal cancer or <5 for breast and prostate cancer) and unfavorable CTC (≥3 or ≥5) was made in the original papers reporting the results of these studies. In practice, a further discrimination in patients with unfavorable CTC can be made when the actual peripheral
| Subject                      | % (n) ≥ 1 | % (n) ≥ 2 | % (n) ≥ 3 | % (n) ≥ 5 | % (n) ≥ 10 | % (n) ≥ 50 | % (n) ≥ 100 | References          |
|-----------------------------|-----------|-----------|-----------|-----------|------------|------------|-------------|---------------------|
| Healthy                     | 2 (330)   | 0.3 (330) | 0 (185)   | 0 (330)   | 0 (330)    | 0 (330)    | 0 (330)     | [4, 13, 47–49]     |
| Nonmalignant                | 5 (398)   | 1 (398)   | 0 (101)   | 0 (101)   | 0 (101)    | 0 (101)    | 0 (101)     |                     |
| Metastatic cancer type      |           |           |           |           |            |            |             |                     |
| Bladder                     | 47 (53)   | 35 (20)   | —         | 25 (53)   | 5 (20)     | 0 (20)     | 0 (53)      | [50, 51]           |
| Breast                      | 55 (200)  | 53 (562)  | 33 (91)   | 38 (671)  | 32 (562)   | 18 (268)   | 12 (562)    | [4, 47, 52–55]     |
| Colorectal                  | 48 (545)  | 34 (455)  | 32 (676)  | 18 (455)  | 12 (455)   | 0 (42)     | 0 (455)     | [8, 56–59]         |
| Gastric                     | 67 (27)   | 56 (27)   | 41 (27)   | 26 (27)   | 19 (27)    | 4 (27)     | 4 (27)      | [13]               |
| Lung, non-small cell        | 46 (57)   | 28 (117)  | 20 (20)   | 11 (57)   | 10 (20)    | 5 (20)     | 5 (20)      | [53, 60, 61]       |
| Lung, small cell            | 95 (38)   | 89 (62)   | 79 (38)   | 79 (38)   | 74 (38)    | 53 (38)    | 47 (38)     | [12, 62]           |
| Ovarian                     | —         | —         | —         | —         | —          | —          | —           | [15]               |
| Pancreatic                  | 35 (72)   | 19 (72)   | 15 (72)   | 8 (72)    | 7 (72)     | 3 (72)     | 3 (72)      | [63, 64]           |
| Prostate                    | 60 (149)  | 80 (40)   | 66 (95)   | 59 (314)  | 53 (40)    | 33 (40)    | 18 (40)     | [10, 48, 49, 53, 65, 66] |

Table 1: Summary of CTC counts in 7.5 mL of blood from patients (n) with various types of metastatic carcinomas. It represents the percentage of patients (%) from the total group of patients (n) above a certain CTC cut-off, detected with the CellSearch System.
blood tumor load is considered. This is illustrated by the Kaplan Meier plots in Figure 4. Blood is drawn before starting a new line of therapy and patients are divided into categories with 0 CTC, 1–4 CTC, 5–24 CTC, and >25 CTC. The difference in survival curves becomes larger after the first cycles of therapy, as the CTC in those patients benefitting from therapy are eliminated. A guide for the interpretation of changes in CTC is described in detail elsewhere [67]. Altogether, it is clear that all CTC will need to be eliminated for a treatment to be truly effective and prolong survival of the patient.

6. Challenges in CTC Identification

The potential of CTC detection and characterization has stimulated the interest of many investigators to develop new CTC platforms [68–81]. The challenge in identifying CTC lies in the detection of these rare cells in blood. In metastatic cancer patients, approximately 1 CTC per mL lies in the detection of these rare cells in blood. The challenge in identifying CTC stimulated the interest of many investigators to develop new CTC platforms [68–81]. The potential of CTC detection and characterization has been reviewed extensively elsewhere [82–85].

One of the approaches we are currently evaluating is filtration of blood to detect CTC that have a relatively large size and stiffness compared to blood cells [86, 87]. In the optimization of this approach, we envisioned the ideal filter for CTC enrichment to be constructed of a stiff, flat material that is impervious to blood cells. To effectively pass blood collected in CellSave tubes, at least 100,000 regularly spaced 5 μm pores with a low porosity are needed [71, 88]. To determine whether CTC have escaped the EpCAM immunomagnetic detection in CellSearch, we constructed a device that collects the blood discarded by the system after immunomagnetic selection of EpCAM+ cells [87, 89]. This blood, lacking EpCAM+ cells, is then passed through a 36 mm2 microsieve with 11.800 5 μm pores. The cells on the filter are immunostained to distinguish CTC from non-CTC and examined by fluorescent microscopy. Figure 5 shows an example of a microsieve; the upper panel shows a bright-field image of a section of a microsieve and the lower panel shows an overlay of fluorescent images of the nucleic acid dye DRAQ5 (blue), CD45-Brilliant Violet staining (red), and cytokeratin-P Elite staining (green). In the image, a CTC of a lung cancer patient is visible among many other cells. The figure also shows that not all nuclei stain with CD45 or cytokeratin. Currently, efforts are ongoing to identify the tissue of origin of these nonidentified cells on the microsieve. Either these cells could still be leukocytes that lost the CD45 antigen or the fluorophore Brilliant Violet does not emit sufficient light to be detected, or the cell is damaged and lost its cytoplasmic membrane. Other alternative explanations may be that these cells are not of hematopoietic lineage, such as endothelial cells, or that these are CTC that do not express the cytokeratins that are recognized by the C11 clone used to stain the cytokeratins. This lack of cytokeratin expression could be a result of the epithelial-mesenchymal transition (EMT) process [90].

Besides cytokeratins, EpCAM expression is used in the majority of CTC enrichment methods based on antibody-capture [91, 92]. Yet EMT could downregulate this protein and other epithelial proteins, leading to a subpopulation of CTC that will be missed during enrichment or detection. CTC that are partially in EMT can coexpress mesenchymal proteins, like vimentin, N-cadherin, and O-cadherin [93, 94]. The CellSearch system only uses a limited panel of cytokeratins for detection and changes in cytokeratin expression during EMT can therefore influence the CTC detection. An expanded panel of cytokeratins is of interest for complete detection and is applied in our search for EpCAM- CTC subpopulations, novel antibodies are of increasing interest to be analyzed as an additional feasible selection marker. CTC populations with expression or lack of expression of epithelial and mesenchymal proteins characterize the complexity and heterogeneity of CTC. The major challenge in addressing these problems is that it is unknown whether CTC are present in the blood sample. If they are present, their heterogeneity of unknown extent is encountered. It requests an increasing diversity in CTC detection and characterization in current and future methods.

7. Assessment of Treatment Targets in CTC

As described earlier, identification of CTC in the CellSearch system uses EpCAM expression for immunomagnetic selection and subsequently DNA, CK, and CD45 staining for identification of the enriched cells. Less strict qualifications for CTC definitions, omitting, for instance, the DNA+ or CD45-
qualification, increase the frequency of objects counted as CTC in patients and controls [46]. EpCAM+ CK+ CTC can be differentiated into intact CTC, CTC fragments, and CTC microparticles. The presence of all these is associated with a relatively short survival in castrate resistant prostate cancer [36]. However, intact CTC containing DNA can provide more information, as they are receptive to molecular and phenotypic characterization. RNA or DNA from CTC can offer a representation of the genetic composition of the tumor and may be especially useful when a tumor biopsy is unavailable. Cell sorting of CTC after CellSearch analysis showed that almost 45% of the exomes in single CTC could be sequenced and whole genome amplification allows for variant calling in single CTC [34].
Figure 5: Cells from CellSearch Waste immunostained on a microsieve. Blood from a lung cancer patient was used for a CellSearch assay. After immunomagnetic selection, part of the sample was discarded by the system and used for filtration on a microsieve with 5 μm pores. Bright-field image of the sieve is shown in (a). (b) shows the sieve with filtered sample. Cells were stained for nucleus (blue), cytokeratin C11 (green), and CD45 (red). Fat arrow points to a CTC, positive in CK. Small arrows point to the absent staining of cells, showing the difficulty of accounting for all cells on the sieve. Image taken on a fluorescence microscope with a 10x (0.45NA) objective.

For breast cancer patients, status of the membrane protein Her-2 may guide their therapy and is of great value for personalized treatment. Usually, tumor biopsies taken at the time of surgery are analysed for their Her-2 status, but may not be representative for the tumor at the time of metastasis. CTC may circumvent this problem and allow real-time determination of the Her-2 status of the tumor. It can be subjective to determine whether or not a protein like Her-2 is expressed and at what level. Tools will be needed to quantify the actual expression levels to reliably investigate the relation to the response of therapy targeting the Her-2 receptor. Figure 6 shows an example of an approach to quantify Her-2 expression on CTC. An automated algorithm is used to identify CTC and provides a numerical value to the level of Her-2 expression on CTC. It is quite obvious that the accuracy of Her-2 expression and the ability to assess its heterogeneity will improve with the number of CTC that are detected. Feasibility for assessment of treatment targets on CTC has been demonstrated for a variety of treatment targets at the protein and genetic level. This supports the notion that CTC indeed can be used to guide personalized therapy in the future, provided that CTC indeed can be isolated from the patient [23, 25–27, 34, 39, 45].

8. Outlook

Treatment of cancer is evolving from chemotherapy towards a more personalized approach, with drugs that recognize specific targets. To define the presence of specific targets, an analysis of the tumor is required at the start of therapy. CTC are likely representatives of the tumor to be treated and can therefore be used as a liquid biopsy. However, sufficient numbers of CTC are required to obtain a representative picture. To arrive at a sufficient number of CTC, a new approach is being explored by the European Consortium “CTC Therapeutic Apheresis” (http://www.utwente.nl/tnw/ctctrap/). The concept of this approach is presented in Figure 7. The CTCTrap combines immunocapture and size-based separation of CTC from their hematopoietic background. A large volume of blood is transported through a matrix and then reintroduced in the body, while CTC are captured in the matrix. After elution, CTC can be individually isolated for further characterization. This can, for example, assess the likelihood that certain therapies will be effective. The CTCTrap is expected to deliver a complete platform to capture, enumerate, and characterize CTC. Detection of all CTC in blood will change the current methods of diagnosis and treatment for patients with known and unknown metastatic disease.
**Disclosure**

Leon W. M. M Terstappen is a consultant of Veridex LLC and his department MCBP of the University of Twente receives research funding from Veridex LLC.

**Conflict of Interests**

Sanne de Wit and Guus van Dalum have no conflict of interests to declare.

**References**

[1] T. R. Ashworth, “A case of cancer in which cells similar to those in the tumours were seen in the blood after death,” *Australasian Medical Journal*, vol. 14, pp. 146–147, 1869.

[2] I. J. Fidler, “The pathogenesis of cancer metastasis: the “seed and soil” hypothesis revisited,” *Nature Reviews Cancer*, vol. 3, no. 6, pp. 453–458, 2003.

[3] W. J. Allard, J. Matera, M. C. Miller et al., “Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases,” *Clinical Cancer Research*, vol. 10, no. 20, pp. 6897–6904, 2004.

[4] M. Cristofanilli, G. T. Budd, M. J. Ellis et al., “Circulating tumor cells, disease progression, and survival in metastatic breast cancer,” *The New England Journal of Medicine*, vol. 351, no. 8, pp. 781–791, 2004.

[5] M. Cristofanilli, D. F. Hayes, G. T. Budd et al., “Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer,” *Journal of Clinical Oncology*, vol. 23, no. 7, pp. 1420–1430, 2005.

[6] D. F. Hayes, M. Cristofanilli, G. T. Budd et al., “Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival,” *Clinical Cancer Research*, vol. 12, no. 14, pp. 4218–4224, 2006.

[7] G. T. Budd, M. Cristofanilli, M. J. Ellis et al., “Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer,” *Clinical Cancer Research*, vol. 12, no. 21, pp. 6403–6409, 2006.

[8] S. J. Cohen, C. J. A. Punt, N. Iannotti et al., “Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer,” *Journal of Clinical Oncology*, vol. 26, no. 19, pp. 3213–3221, 2008.

[9] S. J. Cohen, C. J. A. Punt, N. Iannotti et al., “Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer,” *Annals of Oncology*, vol. 20, no. 7, pp. 1223–1229, 2009.

[10] J. S. de Bono, H. I. Scher, R. B. Montgomery et al., “Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer,” *Clinical Cancer Research*, vol. 14, no. 19, pp. 6302–6309, 2008.

[11] M. G. Krebs, J. Hou, R. Sloane et al., “Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches,” *Journal of Thoracic Oncology*, vol. 7, no. 2, pp. 306–315, 2012.

[12] T. J. N. Hiltrmann, M. M. Pore, A. van den Berg et al., “Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor,” *Annals of Oncology*, vol. 23, no. 11, Article ID mds138, pp. 2937–2942, 2012.

[13] K. Hiraia, H. Takeuchi, H. Hasegawa et al., “Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers,” *Annals of Surgical Oncology*, vol. 15, no. 11, pp. 3092–3100, 2008.

[14] T. Kurihara, T. Itoi, A. Sofuni et al., “Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result,” *Journal of Hepato-Biliary-Pancreatic Surgery*, vol. 15, no. 2, pp. 189–195, 2008.

[15] A. Poveda, S. B. Kaye, R. McCormack et al., “Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer,” *Gynecologic Oncology*, vol. 122, no. 3, pp. 567–572, 2011.

[16] M. Rink, F. K. H. Chun, S. Minner et al., “Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer,” *BJU International*, vol. 107, no. 10, pp. 1668–1675, 2011.

[17] P. Gazzaniga, A. Gradilone, E. de berardinis et al., “Prognostic value of circulating tumor cells in nonmuscule invasive bladder cancer: a cell search analysis,” *Annals of Oncology*, vol. 23, no. 9, Article ID mdr619, pp. 2352–2356, 2012.

[18] M. Naoe, Y. Ogawa, J. Morita et al., “Detection of circulating urothelial cancer cells in the blood using the CellSearch system,” *Cancer*, vol. 109, no. 7, pp. 1439–1445, 2007.

[19] M. H. Strijbos, J. W. Gratama, P. I. M. Schmitz et al., “Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel,” *European Journal of Cancer*, vol. 46, pp. 2027–2035, 2010.
[20] J. L. Rowand, G. Martin, G. V. Doyle et al., “Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas,” Cytometry A, vol. 71, no. 2, pp. 105–113, 2007.

[21] S. Damani, A. Bacconi, O. Libiger et al., “Characterization of circulating endothelial cells in acute myocardial infarction,” Science Translational Medicine, vol. 4, no. 126, Article ID 126ra33, 2012.

[22] C. Rao, T. Bui, M. Connelly et al., “Circulating melanoma cells and survival in metastatic melanoma,” International Journal of Oncology, vol. 38, no. 3, pp. 755–760, 2011.

[23] J. B. Smerage, G. T. Budd, G. V. Doyle et al., “Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer,” Molecular Oncology, vol. 7, no. 3, pp. 680–692, 2013.

[24] S. T. Ligthart, F.-C. Bidard, C. Decraene et al., “Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer,” Annals of Oncology, vol. 24, no. 5, Article ID mds625, pp. 1231–1238, 2013.

[25] J. F. Swennenhuis, A. G. J. Tibbe, R. Levink, R. C. J. Sipkema, and L. W. M. M. Terstappen, “Characterization of circulating tumor cells by fluorescence in situ hybridization,” Cytometry Part A, vol. 75, no. 6, pp. 520–527, 2009.

[26] G. Attard, J. F. Swennenhuis, D. Olmos et al., “Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer,” Cancer Research, vol. 69, no. 7, pp. 2912–2918, 2009.

[27] J. S. De Bono, G. Attard, A. Adjei et al., “Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor,” Clinical Cancer Research, vol. 13, no. 12, pp. 3611–3616, 2007.

[28] American Cancer Society, Cancer Facts & Figures 2013, American Cancer Society, 2013.

[29] J. Ferlay, P. Autier, M. Boniol, M. Heanue, M. Colombet, and S. T. Ligthart, F.-C. Bidard, C. Decraene et al., “Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer,” Annals of Oncology, vol. 24, no. 5, Article ID mds625, pp. 1231–1238, 2013.

[30] A. G. J. Tibbe, M. C. Miller, and L. W. M. M. Terstappen, “Statistical considerations for enumeration of circulating tumor cells,” Cytometry Part A, vol. 71, no. 3, pp. 154–162, 2007.

[31] J. Kraan, S. Sleijfer, M. H. Strijbos et al., “External quality assurance of circulating tumor cell enumeration using the CellSearch system: a feasibility study,” Cytometry B: Clinical Cytometry, vol. 80, no. 2, pp. 112–118, 2011.

[32] J. S. de Bono, and L. W. M. M. Terstappen, “Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival,” PLoS ONE, vol. 6, no. 11, Article ID e27419, 2011.

[33] J. S. Ligthart, F. A. W. Coumans, G. Attard, A. M. Cassidy, J. S. de Bono, and L. W. M. M. Terstappen, “Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival,” PLoS ONE, vol. 6, no. 8, Article ID e67148, 2013.

[34] E. Racila, D. Euhus, A. J. Weiss et al., “Detection and characterization of carcinoma cells in the blood,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 8, pp. 4589–4594, 1998.

[35] L. W. Terstappen, G. T. Budd, G. V. Doyle et al., “Global gene efficiency via controlled aggregation of magnetic nanoparticles,” journal of oncology, vol. 27, no. 1, pp. 49–57, 2005.

[36] J. B. Smerage, G. T. Budd, G. V. Doyle et al., “Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer,” Molecular Oncology, vol. 7, no. 3, pp. 680–692, 2013.

[37] D. F. Hayes, T. M. Walker, B. Singh et al., “Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer,” International Journal of Oncology, vol. 21, no. 5, pp. 1111–1117, 2002.

[38] F. A. W. Coumans, S. T. Ligthart, J. W. Uhr, and L. W. M. M. Terstappen, “Challenges in the enumeration and phenotyping of CTC,” Clinical Cancer Research, vol. 18, no. 20, pp. 5711–5718, 2012.

[39] Z. F. Jiang, M. Cristofanilli, Z. M. Shao et al., “Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (BCRSG004): a multicenter, double-blind, prospective trial,” Annals of Oncology, vol. 24, pp. 2766–2772, 2013.

[40] M. Thalgott, B. Rack, T. Maurer et al., “Detection of circulating tumor cells in different stages of prostate cancer,” Journal of Cancer Research and Clinical Oncology, vol. 139, no. 5, pp. 755–763, 2013.

[41] L. Resel Folkersma, L. San José Mансо, I. Galante Romero, J. Moreno Sierra, and C. Olivier Gómez, “Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer,” Urology, vol. 80, no. 6, pp. 1328–1332, 2012.

[42] O. Higashihara, “Immunomagnetic quantification of circulating tumor cells,” International Journal of Urology, vol. 17, no. 3, pp. 254–258, 2010.
[52] Y. Liu, Q. Liu, T. Wang et al., “Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker,” *BMC Cancer*, vol. 13, article 202, 2013.

[53] F. Farace, C. Massard, N. Vimond et al., “A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas,” *British Journal of Cancer*, vol. 105, no. 6, pp. 847–853, 2011.

[54] J.-Y. Pierga, F.-C. Bidard, C. Cropet et al., “Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial,” *Annals of Oncology*, vol. 24, no. 12, pp. 2999–3004, 2013.

[55] K. Tryfonidis, I. Boukouvias, N. Xenidis et al., “A multicenter phase I-II study of docetaxel plus ipirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer,” *Breast*, vol. 22, no. 6, pp. 1171–1177, 2013.

[56] B. Mostert, Y. Jiang, A. M. Sieuwerts et al., “KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue,” *International Journal of Cancer*, vol. 135, no. 1, pp. 130–141, 2013.

[57] J. T. Park, S. J. Lee, D. K. Kim, N. S. Heo, J. Y. Park, and S. Y. Lee, “Development of label-free optical diagnosis for sensitive detection of influenza virus with genetically engineered fusion protein,” *Talanta*, vol. 89, pp. 246–252, 2012.

[58] Y. Kuboki, S. Matsusaka, S. Minowa et al., “Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer,” *Anticancer Research*, vol. 33, no. 9, pp. 3905–3910, 2013.

[59] J. Sastre, M. Vidaurreta, A. Gómez et al., “Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab,” *Clinical Colorectal Cancer*, vol. 12, pp. 280–286, 2013.

[60] O. Juan, J. Vidal, R. Gisbert, J. Muñoz, S. Maciá, and J. Gómez-Codina, “Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine,” *Clinical & Translational Oncology*, vol. 16, pp. 637–643, 2014.

[61] M. G. Krebs, R. Sloane, L. Priest et al., “Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer,” *Journal of Clinical Oncology*, vol. 29, no. 12, pp. 1556–1563, 2011.

[62] T. Naito, F. Tánaka, A. Ono et al., “Prognostic impact of circulating tumor cells in patients with small cell lung cancer,” *Journal of Thoracic Oncology*, vol. 7, no. 3, pp. 512–519, 2012.

[63] C. C. Khoja, A. Backen, R. Sloane et al., “A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker,” *British Journal of Cancer*, vol. 106, no. 3, pp. 508–516, 2012.

[64] M. S. Khan, T. Tsiganis, M. Rashid et al., “Circulating tumor cells and EpCAM expression in neuroendocrine tumors,” *Clinical Cancer Research*, vol. 17, no. 2, pp. 337–345, 2011.

[65] R. J. Amato, V. Melnikova, Y. Zhang et al., “Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer,” *Urology*, vol. 81, no. 6, pp. 1303–1307, 2013.

[66] M. J. M. Magbanua, E. V. Sosa, J. H. Scott et al., “Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer,” *BMC Cancer*, vol. 12, article 78, 2012.

[67] F. A. W. Coumans, S. T. Ligthart, and L. W. M. M. Terstappen, “Interpretation of changes in circulating tumor cell counts,” *Translational Oncology*, vol. 5, no. 6, pp. 486–491, 2012.

[68] H. W. Hou, M. E. Warkiani, B. L. Khoo et al., “Isolation and retrieval of circulating tumor cells using centrifugal forces,” *Scientific Reports*, vol. 3, article 1259, 2013.

[69] E. Ozkumur, A. M. Shah, J. C. Ciciliano et al., “Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells,” *Science Translational Medicine*, vol. 5, no. 179, Article ID 179ra47, 2013.

[70] H. Choi, K. B. Kim, C. S. Jeon et al., “A label-free DC impedance-based microcylinder for circulating rare cancer cell counting,” *Lab on a Chip*, vol. 13, no. 5, pp. 970–977, 2013.

[71] F. A. W. Coumans, G. van Dalum, M. Beck, and L. W. M. M. Terstappen, “Filter characteristics influencing circulating tumor cell enrichment from whole blood,” *PLoS ONE*, vol. 8, no. 4, Article ID e61770, 2013.

[72] T. J. Park, S. J. Lee, D. K. Kim, N. S. Heo, J. Y. Park, and S. Y. Lee, “Development of label-free optical diagnosis for sensitive detection of influenza virus with genetically engineered fusion protein,” *Talanta*, vol. 89, pp. 246–252, 2012.

[73] D. Issadore, J. Chung, H. Shao et al., “Ultrasonic clinical enumeration of rare cells ex vivo using a micro-hall detector,” *Science Translational Medicine*, vol. 4, no. 141, p. 141ra92, 2012.

[74] M. S. Kim, T. S. Sim, Y. J. Kim et al., “SSA-MOA: a novel CTC isolation platform using selective size amplification (SSA) and a multi-obstacle architecture (MOA) filter,” *Lab on a Chip*, vol. 12, no. 16, pp. 2874–2880, 2012.

[75] S. Nagrath, L. V. Sequist, S. Maheswaran et al., “Isolation of rare circulating tumour cells in cancer patients by microchip technology,” *Nature*, vol. 450, no. 7173, pp. 1235–1239, 2007.

[76] S. L. Stott, C. Hsu, D. I. Tsukrov et al., “Isolation of circulating tumor cells using a microvortex-generating herringbone-chip,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 43, pp. 18392–18397, 2010.

[77] A. H. Talasaz, A. A. Powell, D. E. Huber et al., “Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 10, pp. 3970–3975, 2009.

[78] B. J. Kirby, M. Jodari, M. S. Lofus et al., “Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device,” *PLoS ONE*, vol. 7, no. 4, Article ID e35976, 2012.

[79] H. K. Lin, S. Zheng, A. J. Williams et al., “Portable filter-based microdevice for detection and characterization of circulating tumor cells,” *Clinical Cancer Research*, vol. 16, no. 20, pp. 5011–5018, 2010.

[80] A. D. Hughes, J. Mattison, L. T. Western, J. D. Powderly, B. G. O’Ryan, and M. R. King, “Microtube device for selectin-mediated capture of viable circulating tumor cells from blood,” *Clinical Chemistry*, vol. 58, no. 5, pp. 846–853, 2012.

[81] D. Adams, P. Zhu, and O. Makarova, “The systematic study of circulating tumor cell isolation using lithographic microfilters,” *RSC Advances*, vol. 4, no. 9, pp. 4334–4342, 2014.

[82] T. M. Gorges and K. Pantel, “Circulating tumor cells as therapy-related biomarkers in cancer patients,” *Cancer Immunology, Immunotherapy*, vol. 62, no. 5, pp. 931–939, 2013.

[83] M. Balic, H. Lin, A. Williams, R. H. Datar, and R. J. Cote, “Progress in circulating tumor cell capture and analysis: implications for cancer management,” *Expert Review of Molecular Diagnostics*, vol. 12, no. 3, pp. 303–312, 2012.
[84] K. Pantel, R. H. Brakenhoff, and B. Brandt, “Detection, clinical 
relevance and specific biological properties of disseminating tumour cells,” *Nature Reviews Cancer*, vol. 8, no. 5, pp. 329–340, 
2008.

[85] A. M.C. Barradas and L. W. M. M. Terstappen, “Towards 
the biological understanding of CTC: capture technologies, 
definitions and potential to create metastasis,” *Cancers*, vol. 5, 
no. 4, pp. 1619–1642, 2013.

[86] G. van Dalum, A. Lenferink, and L. W. M. M. Terstappen, 
“Detection of EpCAM negative circulating tumor cells in 
CellSearch waste,” in *Proceedings of the 104th Annual Meeting 
of the American Association for Cancer Research*, abstract 3846, 
Philadelphia, Pa, USA, 2013.

[87] S. de Wit, G. van Dalum, J. van Dalum et al., “Circulating 
tumor cells in metastatic lung cancer enriched by EpCAM 
expression and physical characteristics,” in *Proceedings of the 
105th Annual Meeting of the American Association for Cancer 
Research*, Abstract 4825, San Diego, Calif, USA, April 2014.

[88] F. A. W. Coumans, G. van Dalum, M. Beck, and L. W. M. 
M. Terstappen, “Filtration parameters influencing circulating 
tumor cell enrichment from whole blood,” *PLoS ONE*, vol. 8, 
no. 4, Article ID e61774, 2013.

[89] G. van Dalum, A. Lenferink, and L. Terstappen, “Detection of 
EpCAM negative circulating tumor cells in CellSearch waste,” in 
*Proceedings of the 104th Annual Meeting of the American 
Association for Cancer Research*, Washington, DC, USA, 2013.

[90] S. A. Joosse, J. Hannemann, J. Spötter et al., “Changes in keratin 
expression during metastatic progression of breast cancer: 
Impact on the detection of circulating tumor cells,” *Clinical 
Cancer Research*, vol. 18, no. 4, pp. 993–1003, 2012.

[91] M. G. Krebs, R. L. Metcalf, L. Carter, G. Brady, F. H. Blackhall, 
and C. Dive, “Molecular analysis of circulating tumour cells— 
biology and biomarkers,” *Nature Reviews Clinical Oncology*, vol. 
11, no. 3, pp. 129–144, 2014.

[92] T. W. Friedlander, G. Premasekharan, and P. L. Paris, “Looking 
back, to the future of circulating tumour cells,” *Pharmacology & 
Therapeutics*, vol. 142, no. 3, pp. 271–280, 2014.

[93] G. Kallergi, M. A. Papadaki, E. Politaki, D. Mavroudis, V. Geor-
goulas, and S. Agelaki, “Epithelial to mesenchymal transition 
markers expressed in circulating tumour cells of early and 
metastatic breast cancer patients,” *Breast Cancer Research*, vol. 
13, no. 3, article R59, 2011.

[94] A. J. Armstrong, M. S. Marengo, S. Oltean et al., “Circulating 
tumor cells from patients with advanced prostate and breast 
cancer display both epithelial and mesenchymal markers,” 
*Molecular Cancer Research*, vol. 9, no. 8, pp. 997–1007, 2011.
